GC001 / Hangzhou Gongchu Biotech - LARVOL DELTA

Efficacy and safety of GC001: an oncolytic vaccinia virus expressing STRIP1 shRNA. (PubMed, Br J Cancer) - "Our study reveals dual mechanisms of GC001: viral replication and cytotoxicity potentiation through ROS-Hippo pathway, and oxidative stress-mediated anti-tumour immune responses. Studies have demonstrated robust anti-tumour efficacy and favourable safety profile of GC001, thereby establishing it as a promising oncolytic VV candidate for clinical development."

Journal • Oncology • STRN

A Phase I Clinical Study of Intratumoral Injection GC001 in Patient With Recurrent or Progressive Gliomas (clinicaltrials.gov) - P1 | N=35 | Recruiting | Sponsor: GONGCHU Biotechnology Co., Ltd

New P1 trial • Oncolytic virus • Brain Cancer • CNS Tumor • Glioma • Oncology • Solid Tumor • CD4 • IFNG • IL10 • IL6 • PD-1 • TNFA